Rita Axelrod

Professor

Thomas Jefferson University
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (16)

Figure s4. Gene set enrichment analysis (GSEA) across baseline responder vs. nonresponder comparisons and baseline vs. post-treatment analyses in the durvalumab-metformin clinical trial and other clinical trial cohorts. GSEA was performed to assess differences between baseline responders and nonresponders, as well as baseline vs. post-treatment samples

Year:

2025

Purpose: Immune checkpoint inhibitors (ICI) have demonstrated clinical benefit in head and neck squamous cell carcinoma (HNSCC); however, single-agent efficacy is limited, leaving significant unmet needs. Metformin may synergize with ICIs, offering promise to improve response rates. We leveraged multiomic data from a randomized, presurgical neoadjuvant trial (NCT03618654) evaluating a single infusion of the anti–PD-L1 ICI durvalumab with or without daily, standard dose metformin in previously untreated, nondiabetic patients with HNSCC to understand predictors of response and the effect of combination therapy. Patients and Methods: Clinical, pathologic, and correlative data were analyzed to investigate response and resistance mechanisms. We present an in-depth multiomic analysis of primary tumor specimens to study treatment response/resistance in human papillomavirus–positive HNSCC. Results: Baseline samples revealed that myofibroblastic cancer-associated fibroblast and extracellular matrix signatures were enriched in durvalumab plus metformin nonresponders, which were localized to the leading tumor edge on spatial transcriptomics. In contrast, baseline responder samples were enriched for the Langerhans-like dendritic cell (DC) state and IFN signatures. Treatment increased intratumoral CD8 + T-cell and IFN signatures and peripheral blood CCL2 levels. Responders demonstrated macrophage and DC enrichment and antigen processing and presentation upregulation. Enrichment of cell cycle–related gene sets, specifically the MYC targets V1 hallmark gene set, correlated with nonresponse. Conclusions: Early response and resistance dynamics for durvalumab plus metformin in human papillomavirus–positive HNSCC reveal baseline extracellular matrix–myofibroblastic cancer-associated fibroblast as predictive of nonresponse. In contrast, responders were distinguished by baseline enrichment in the Langerhans-like DC state and posttreatment antigen-presenting gene sets.

Year:

2025

Figure s5. Baseline immune cell composition in responders and nonresponders across bulk, tumor, and stromal compartments & Immune cell deconvolution analysis in bulk tumor samples of responders and nonresponders before and after durvalumab-metformin treatment.

Year:

2025

Figure s11. Carcinoma ecotype differences at baseline and after treatment in HPV+ HNSCC responders and non-responders. This figure illustrates differences in carcinoma ecotype composition before and after treatment in HPV+ HNSCC patients

Year:

2025

Supplement Figure 3: Signature-based Biomarkers. A: Signature-Based biomarkers for HPV negative patients. B: Signature-based biomarkers for HPV positive patients. ‘Primary Path Response’ refers to analysis based on the pTR at the primary site alone. ‘Overall path response’ refers to analysis based on primary + lymph node response.

Year:

2025

Supplement Figure 1: Waterfall Plots. A: Degree of pathologic treatment response (pTR) at the lymph nodes. B: Degree of pathologic response at the primary site, stratifed by treatment arm. C: Degree of RECIST response of primary tumor site (yellow) and lymph nodes (purple), stratifed by treatment arm.

Year:

2025

Supplement Table 4A-4B: The following is a comprehensive list of the top 20 functional enrichments in the B cell (A) and CAF2 (B) gene sets utilizing STRING database to analyze protein-protein interaction pairs among the leading edge.

Year:

2025

Supplement Table 2A-2E: GSEA quantitative data for the B cell gene sets and CAF2 gene set for Post- vs Pre-treatments Responders vs Non responders. The following is a comprehensive list of supervised B-cell (A-C) and CAF (D-E) enrichment scores, normal enrichment scores, p-values, and q-values for the included gene sets.

Year:

2025

Supplementary Figure 2: Effect of IDO inhibitor BMS986205 on response rate and the tryptophan kynurenine pathway. A and B: IDO1 gene expression levels and tryptophan kynurenine pathway activity score, respectively, compared between baseline samples of responders (R) and non-responders (NR) on nivolumab + BMS986205 and nivolumab-only therapies. C: Tryptophan kynurenine pathway activity score compared between baseline and post-treatment samples of R and NR on nivolumab + BMS986205 and nivolumab-only therapies. - ns, *p

Year:

2025

Purpose: Neoadjuvant chemotherapy for structure preservation (SP) in nasal and paranasal sinus squamous cell carcinoma (NPNSCC) has been described in single-institution studies but not in randomized studies. EA3163 was a randomized study investigating whether cytoreductive neoadjuvant chemotherapy would improve SP or overall survival (OS). Patients and Methods: Patients with T3/T4a and select T4b NPNSCC requiring orbital or base of skull (BOS) resection were randomized to surgery (arm A) versus surgery preceded by docetaxel/cisplatin for three cycles (arm B). The degree of anticipated SP (orbit and BOS) was required preoperatively and after chemotherapy. SP was noted at surgery. Co-primary objectives were the SP rate (orbit/BOS) and OS. Eighty-two patients needed to be accrued for 81% power with a 0.1 one-sided alpha using Fisher’s exact test for SP rate and 83% with a 0.1 one-sided alpha using the log-rank test for OS. Results: Among 23 evaluable patients, the overall SP rate was 30%: 15% in arm A ( N = 2/13; 95% confidence interval (CI), 1.9%–45.4%) and 50% in arm B ( N = 5/10; 95% CI, 18.7%–81.3%; P = 0.17). Among 18 patients with pathologic T3/T4a disease, the overall SP rate was 39%: 18% in arm A ( N = 2/11; 95% CI, 2.3%–51.8%) and 71% in arm B ( N = 5/7; 95% CI, 29.0%–96.3%; P = 0.049). Orbit and BOS-specific preservation rates were 38% (95% CI, 8.5%–75.5%) versus 83% (95% CI, 35.9%–99.6%) and 33% (95% CI, 9.9%–65.1%) versus 67% (95% CI, 29.9%–92.5%) in arm A versus B, respectively. The most common grade ≥3 toxicities included mucositis, anemia, nausea and lymphopenia (all >10%). No grade 5 events were reported. Conclusions: These results support neoadjuvant chemotherapy as an effective intervention for SP in T3/T4a NPNSCC and deserve further evaluation.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (30)

Andrew South

Oros Family Professor in Rare Skin Diseases

University of Wisconsin-Madison

UNITED STATES
View details

Fenghai Duan

Professor

Brown University

UNITED STATES
View details

Christopher Le

Professor

University of Arizona College of Medicine

UNITED STATES
View details

Megan Roche

Thomas Jefferson University

UNITED STATES
View details

Ramkrishna Mitra

Assistant Professor

Thomas Jefferson University

UNITED STATES
View details

Nabil F. Saba

-

UNITED STATES
View details

Nolan B. Seim

Assistant Professor

Ohio State University

UNITED STATES
View details

David Cognetti

department of surgery thomas jefferson university hospital sidney kimmel medical college philadelphia university and tho

UNITED STATES
View details

Peter H. Hwang

-

UNITED STATES
View details

Joseph Curry

Associate Professor

Thomas Jefferson University Hospital

UNITED STATES
View details

Tingting Zhan

Associate Professor

Thomas Jefferson University

UNITED STATES
View details

Rathan M. Subramaniam

Duke University

UNITED STATES
View details

George Prendergast

Professor, President & CEO

Lankenau Institute for Medical Research

UNITED STATES
View details

Ehab Y. Hanna

-

UNITED STATES
View details

Barbara Burtness

Professor

Yale University School of Medicine

UNITED STATES
View details

Hushan Yang

Professor

Thomas Jefferson University

UNITED STATES
View details

Benjamin Leiby

Professor

Thomas Jefferson University

UNITED STATES
View details

Charalambos Solomides

Professor

Thomas Jefferson University

UNITED STATES
View details

Rajanikanth Vadigepalli

Thomas Jefferson University

UNITED STATES
View details

Paul Swiecicki

University of Michigan

UNITED STATES
View details

Scott W. Keith

Thomas Jefferson University

UNITED STATES
View details

Larry Harshyne

Associate Professor

Thomas Jefferson University

UNITED STATES
View details

Carl Snyderman

Professor

University of Pittsburgh

UNITED STATES
View details

Jennifer M. Johnson

Thomas Jefferson University

UNITED STATES
View details

Dong M. Shin

Professor

Emory University

UNITED STATES
View details

Chukwuemeka Ikpeazu

Associate Professor

University of Miami Miller School of Medicine

UNITED STATES
View details

John R. Eisenbrey

Thomas Jefferson University

UNITED STATES
View details

Ubaldo Martinez-Outschoorn

Associate Professor

Thomas Jefferson University

UNITED STATES
View details

Stacey Gargano

Thomas Jefferson University Hospital

UNITED STATES
View details

Adam J. Luginbuhl

-

UNITED STATES
View details